In a CALGB study including only CN-AML patients older than 60 years, miR-3151 was identified as an independent prognostic factor.22 In the same study, patients with overexpression of both miR-3151 and BAALC had the worst outcome, while those with low levels of both had the best outcome. This evidence concerns the gene BAALC and acute myeloid leukemia.